Earnings Calls In Brief
This article was originally published in The Gray Sheet
J&J/Synthes deal on track
You may also be interested in...
The first company to enter the drug-eluting stent market will now be the first to depart.
J&J/Codman’s Orbit Galaxy
Abbott expects it will take several months to resume shipments of its MitraClip transcatheter mitral valve repair system following a voluntary global recall, but the firm says the recall is not likely to impact anticipated U.S. approval of the device later this year.